Литература. 
Многомерная биология XXI века и клиническая лабораторная диагностика

1. Pusztai L. Hess K. R, Clinical trial design for microarray predictive marker discovery and assessment. Annals of Oncology. 2004, 15: 1731−1737.

2. He YD. Genomic approach to biomarker identification and its recent applications. Cancer Biomark. 2006;2(3−4):103−33.

3. Pusztai L. Chips to bedside: incorporation of microarray data into clinical practice. Clin Cancer Res. 2006; 12(24):7209−7214.

4. Patino WD, Mian OY, Kang JG, Matoba S, Bartlett LD, Holbrook B, Trout HH, Kozloff L, Hwang PM. Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci U S A. 2005;102(9):3423−3488.

5. Vitzthum F, Behrens F Anderson N L, Shaw JH Proteomics: From Basic Research to Diagnostic Application. A Review of Requirements Needs Journal of Proteome Research 2005, 4, 1086−1097.

6. Tsiridis E, Giannoudis PV. Transcriptomics and proteomics: advancing the understanding of genetic basis of fracture healing. Injury. 2006; 37 Suppl 1: S13−9.

7. Filipowicz W. Imprinted expression of small nucleolar RNAs in brain: time for RNomics. Proc Natl Acad Sci USA. 2000; 97(26):14 035−7.

8. Beggs JD, Tollervey D. Crosstalk between RNA metabolic pathways: an RNOMICS approach. Nat Rev Mol Cell Biol. 2005; 6(5):423−439.

9. Huttenhofer A, Vogel J. Experimental approaches to identify non-coding RNAs. Nucleic Acids Res. 2006; 34(2):635−646.

10. Многомерная биология XXI века и клиническая лабораторная диагностика (продолжение…).

11. Backofen R, Bernhart SH, Flamm C, Fried C, Fritzsch G, Hackermuller J, Hertel J, Hofacker IL, Missal K, Mosig A, Prohaska SJ, Rose D, Stadler PF, Tanzer A, Washietl S, Will S. RNAs everywhere: genome-wide annotation of structured RNAs. J Exp Zoolog B Mol Dev Evol. 2006.

12. Kauppinen S, Vester B, Wengel J. Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics.: Handb Exp Pharmacol. 2006; (173):405−422.

13. Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 2006; 25(46):6220−6227.

14. Wittmann-Liebold B, Graack HR, Pohl T. Two-dimensional gel electrophoresis as tool for proteomics studies in combination with protein identification by mass spectrometry. Proteomics. 2006; 6(17): 4688−4703.

15. Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, Ouzounian M, MacLennan DH, Emili A, Liu PP. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol. 2006; 48(9):1733−1741.

16. Chung CH, Levy S, Chaurand P, Carbone DP. Genomics and proteomics: Emerging technologies in clinical cancer research. Crit Rev Oncol Hematol. 2007; 61(1):1−25.

17. Whiteley GR. Proteomic patterns for cancer diagnosis—promise and challenges. Mol Biosyst. 2006; 2(8):358−363.

18. Smith JD, Topol EJ. Identification of atherosclerosis-modifying genes: pathogenic insights and therapeutic potential. Expert Rev Cardiovasc Ther. 2006; 4(5):703−709.

19. Mariappan D, Winkler J, Hescheler J, Sachinidis A. Cardiovascular genomics: a current overview of in vivo and in vitro studies. Stem Cell Rev. 2006; 2(1):59−66.

20. Arrell DK, Neverova I, Van Eyk JE Cardiovascular Proteomics: Evolution and Potential. Circ Res. 2001;88:763−773.

21. Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, Ouzounian M, MacLennan DH, Emili A, Liu PP. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol. 2006; 48(9):1733−1741.

22. Matt P, Carre Tl, White M, Lefkovits I, PhD, Van Eyk J, Proteomics in cardiovascular surgery. J Thoracic and Cardiovascular Surgery, 2007, 133, 1.210- 214.

23. Bijnens AP, Lutgens E, Ayoubi T, Kuiper J, Horrevoets AJ, Daemen MJ. Genome-wide expression studies of atherosclerosis: critical issues in methodology, analysis, interpretation of transcriptomics data. Arterioscler Thromb Vasc Biol. 2006; 26(6):1226−1235.

24. Omenn G S., States D J. Adamski M et al Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database Proteomics 2005, 5, 3226−3245.

25. Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res. 2006; 66(11):5540−5541.

26. States DJ, Omenn GS, Blackwell TW, et al Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol. 2006 Mar;24(3):333−338.

27. Omenn G S. Strategies for plasma proteomic profiling of cancers Proteomics 2006, 6, 5662−5673.

28. Gnatenko DV, Perrotta PL, Bahou WF. Proteomic approaches to dissect platelet function: Half the story. Blood. 2006, 108(13):3983−3991.

29. Patino WD, Mian OY, Kang JG, Matoba S, Bartlett LD, Holbrook B, Trout HH 3rd, Kozloff L, Hwang PM. Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci USA. 2005; 102(9):3423−3428.

30. Kolch W, Miischak H, Pitt The molecular make-up of a tumour: proteomics in cancer research Clinical Science (2005) 108, 369−383.

31. Asa SL. Ezzat S Genetics and Proteomics of Pituitary Tumors. Endocrine, 2005, 28, 1, 43−47.

32. Kallioniemi O. Functional genomics and transcriptomics of prostate cancer: promises and limitations. BJU Int. 2005; 96 Suppl 2:10−15.

33. Petrik V, Loosemore A, Howe FA, Bell BA, Papadopoulos MC. OMICS and brain tumour biomarkers. Br J Neurosurg. 2006; 20(5):275−280.

34. Whiteley GR Proteomic patterns for cancer diagnosis—promise and challenges. Mol Biosyst. 2006;2(8):358−363.

35. Solassol J, Jacot W, Lhermitte L, Boulle N, Maudelonde T, Mange A. Clinical proteomics and mass spectrometry profiling for cancer detection/ Expert Rev Proteomics, 2006, 3(3). 311−320.

36. Chung CH, Levy S, Chaurand P, Carbone DP Genomics and proteomics: Emerging technologies in clinical cancer research. Crit Rev Oncol Hematol. 2007; 61 (1):1−25.

37. Anensen N, Haaland I, D’Santos C, Van Belle W, Gjertsen BT. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. Curr Pharm Biotechnol. 2006, 7(3):199−207.

38. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med. 2006; 12(12):580−587.

39. Croce C. MicroRNAs in leukemia. Clin Adv Hematol Oncol. 2006; 4(8):577−578.

40. Hammond SM. RNAi, microRNAs, and human disease. Cancer Chemother Pharmacol. 2006; 58 Suppl 7:63−68.

41. Wijnhoven BP, Michael MZ, Watson DI. MicroRNAs and cancer. J Surg. 2007; 94(1):23−30.

42. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2007;28(1):2−1.

43. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006 Aug 16;.

44. Esquela-Kerscher A, Slack FJ. Oncomirs — microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259−269.

45. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2006 Dec 5.

46. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2006 Dec 5.

47. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065−7070.

48. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, Croce CM. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006; 24(29):4677−4684.

49. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene. 2006 ;25(46):6202−6210.

50. Esquela-Kerscher A, Slack FJ. Oncomirs — microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259−269.

51. Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res. 2006; 66 (22): 10 843−10 848.

52. Wurdinger T, Costa FF. Molecular therapy in the microRNA era. Pharmacogenomics J. 2006 Dec 26;.

53. Jain KK. Commercial potential of RNAi. Mol Biosyst. 2006; 2(11):523−526.

54. Vidal BC, Bonventre JV, I-Hong Hsu S. Towards the application of proteomics in renal disease diagnosis. Clin Sci (Lond). 2005; 109 (5):421−430.

55. Thongboonkerd V. Proteomic analysis of renal diseases: unraveling the pathophysiology and biomarker discovery. Expert Rev Proteomics. 2005; 2(3):349−366.

56. Carter D. Cellular transcriptomics — the next phase of endocrine expression profiling. Trends Endocrinol Metab. 2006; 17 (5):192−198.

57. Hsu SY, Hsueh AJ Hormonal genomics. Endocr Rev. 2002; 23(3):369−381.

58. Giordano TJ. Gene expression profiling of endocrine tumors using DNA microarrays: progress and promise. Endocr Pathol. 2003; 14(2):107−116.

59. Polychronakos C. Impact of the human genome project on pediatric endocrinology. Horm Res. 2003;59(2):55−65.

60. Qian X, Scheithauer BW, Kovacs K, Lloyd RV. DNA microarrays: recent developments and applications to the study of pituitary tissues. Endocrine. 2005; 28(1):49−56.

61. Stratakis CA. Applications of genomic medicine in endocrinology and post-genomic endocrine research. Hormones (Athens). 2005 ;4(1):38−44.

62. Leo CP, Hsu SU, Hsueh AJW/ Hormonal Genomics. Endocrine Reviews, 2002, 23(3):369−381.

63. Hayashi S. Prediction of hormone sensitivity by DNA microarray. Biomed Pharmacother. 2004; 58(1):1−9.

64. Francois E, Wang DY, Fulthorpe R, Liss SN, Edwards EA. DNA microarrays for detecting endocrine-disrupting compounds. Biotechnol Adv. 2003; 22(1−2):17−26.

65. Naciff JM, Daston GP. Toxicogenomic approach to endocrine disrupters: identification of a transcript profile characteristic of chemicals with estrogenic activity. Toxicol Pathol. 2004; 32 Suppl 2:59−70.

66. Kralj M, Kraljevic S, Sedic M, Kurjak A, Pavelic K. Global approach to perinatal medicine: functional genomics and proteomics. J Perinat Med. 2005; 33(1):5−16.

67. Romero R, Tarca AL, Tromp G Insights into the Physiology of Childbirth Using Transcriptomics. PLoS Medicine, 2006, 3, 6, 739 — 741.

68. Romero R, Espinoza J, Gotsch F, Kusanovic J, Friel L, Erez O, Mazaki-Tovi S, Than N, Hassan S, Tromp G The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. BJOG. 2006; 113(s3):118−135.

69. Crameri R. The potential of proteomics and peptidomics for allergy and asthma Allergy. 2005; 60(10):1227−12 237.

70. Harwanegg Ch, Hiller R. Protein microarrays for the diagnosis of allergic diseases: state-of-the-art and future developmentю Allerg Immunol (Paris). 2006; 38(7):232−236.

71. Rokutan K, Morita K. Gene expression profiling in peripheral blood leukocytes as a new approach for assessment of human stress response. J Med Invest. 2005; 52 (3−4):137−144.

72. Paulson L, Persson R, Karlsson G, Silberring J, Bierczynska-Krzysik A, Ekman R, Westman-Brinkmalm A. Proteomics and peptidomics in neuroscience. Experience of capabilities and limitations in a neurochemical laboratory. J Mass Spectrom. 2005; 40(2):202−123.

73. Becker M, Schindler J, Nothwang HG. Neuroproteomics — the tasks lying ahead. Electrophoresis. 2006; 27(13):2819−2829.

74. Sharp FR, Xu H, Lit L, Walker W, Apperson M, Gilbert DL, Glauser TA, Wong B, Hershey A, Liu DZ, Pinter J, Zhan X, Liu X, Ran R. The future of genomic profiling of neurological diseases using blood. Arch Neurol. 2006; 63(11):1529−1536.

75. Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM. Genetics, transcriptomics, and proteomics of Alzheimer’s disease. J Clin Psychiatry. 2006; 67(4):652−670.

76. Fountoulakis M, Kossida S. Proteomics-driven progress in neurodegeneration research. Electrophoresis. 2006; 27(8):1556−1573.

77. Fonteh AN, Harrington RJ, Huhmer AF, Biringer RG, Riggins JN, Harrington MG. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis Markers. 2006;22(1−2):39−64.

78. Wei-Min Gao, Chadha MS, Berger RP et al A Gel-Based Proteomic Comparison of Human Cerebrospinal Fluid between Inflicted and Non-Inflicted Pediatric Traumatic Brain Injury J Neurotrauma, 2007, 24, 1, 43−53.

79. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, Greenberg ME. A brain-specific microRNA regulates dendritic spine development. Nature. 2006; 439(7074):283−289.

80. Saba R, Booth SA. Target labelling for the detection and profiling of microRNAs expressed in CNS tissue using microarrays. BMC Biotechnol. 2006 Dec 12;6:47.

81. Ashraf SI, Kunes S. A trace of silence: memory and microRNA at the synapse. Curr Opin Neurobiol. 2006; 16(5):535−539.

82. Chen W, Jensen LR, Gecz J, Fryns JP, Moraine C, de Brouwer A, Chelly J, Moser B, Ropers HH, Kuss AW. Mutation screening of brain-expressed X-chromosomal miRNA genes in 464 patients with nonsyndromic X-linked mental retardation. Eur J Hum Genet. 2006 Dec 20;.

83. Krishnan KR. Psychiatric disease in the genomic era: rational approach. Mol Psychiatry. 2005;10 (11): 978−984.

84. Lakhan S E Schizophrenia proteomics: biomarkers on the path to laboratory medicine? Diagnostic Pathology, 2006, 1:11−13.

85. Mirnics K, Levitt P, Lewis DA. Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry. 2006; 60(2):163−176.

86. La YJ, Wan CL, Zhu H, Yang YF, Chen YS, Pan YX, Feng GY, He L. Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J Neural Transm. 2006 Dec 14;.

87. Yang Y, Wan C, Li H et al. Altered Levels of Acute Phase Proteins in the Plasma of Patients with Schizophrenia Anal. Chem, 2006., 78 (11), 3571 -3576.

88. Jiang L, Lindpaintner K, Li HF, Gu NF, Langen H, He L, Fountoulakis M. Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids. 2003;25(1):49−57.

89. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C. Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov Disord. 2006 Dec 18;.

90. Herbert M. R,. Russo J. P, Yang S, Roohi J, Blaxill M. Kahler S. G, Cremer L., Hatchwell E. Autism and environmental genomics. NeuroToxicology 27 (2006) 671−684.

91. Avissar S, Schreiber G., Toward molecular diagnostics of mood disorders in psychiatry. Trends Mol Med. 2002; 8(6): 294−300.

92. Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB, Kuczenski R, Niculescu AB. Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol Psychiatry. 2004; 9(11):1007−1029.

93. Alesci S, Rodak M, Ilias I, Zhou R Manji HK. The genomics of mood disorders. Prog Brain Res. 2006; 158:129−139.

94. Uys JD Stein DJ Daniels WM. Neuroproteomics: relevance to anxiety disorders. Curr Psychiatry Rep. 2006; 8(4):286−290.

95. Ke Xu, Ernst M, Goldman D Imaging Genomics Applied to Anxiety, Stress Response and Resiliency Neuroinformatics, 2007.

96. Ebstein RP, The molecular genetic architecture of human personality: beyond self-report questionnaires Molecular Psychiatry (2006), 1−19.

97. Ding Y.C. et al. Evidence of positive selection acting at the human dopamine receptor D4 gene locus // Proc. Natl. Acad. Sci. 2002. № 99 (1). P. 309−314.

98. Nakamura T., Muramatsu T., Ono Y., et al. Serotonin transporter gene regulatory region polymorphism and anxiety-related traits in the Japanese. Am. J. Med. Genet. 1997, 74, 544−545.

99. Westphal S.P., Your very own sequence. New Scientist, 12 October 2002. P12−13.

100. Cirelli C. Cellular consequences of sleep deprivation in the brain. Sleep Med Rev. 2006; 10(5):307−321.

101. Griffin JL, Nicholls AW. Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. Pharmacogenomics. 2006;7(7):1095−1107.

102. Schnackenberg LK, Beger RD. Monitoring the health to disease continuum with global metabolic profiling and systems biology. Pharmacogenomics. 2006; 7(7):1077−1086.

103. Hollywood K, Brison DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics. 2006 ;6(17):4716−4723.

104. van der Greef J, Hankemeier T, McBurney RN. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics. 2006; 7(7):1087−94.

105. Schnackenberg LK, Beger RD. Monitoring the health to disease continuum with global metabolic profiling and systems biology. Pharmacogenomics. 2006; 7(7):1077−1086.

106. Duarte NC, Becker SB, Jamshidi N, Thiele I, Mo ML, Vo TD, Rohith Srivas R, Palsson B. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl. Acad. Sci. USA, Published online January 31, 2007.

107. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, McKilligin E, Mosedale DE, Grainger DJ. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med. 2002; 8(12):1439−1444.

108. Wishart DS. Metabolomics in monitoring kidney transplants Curr Opin Nephrol Hypertens. 2006 ;15(6):637−642.

109. Nicholson JK, Connelly J, Lindon JC. Holmes E. Metabonomics: a platform for studying drug toxicity and gene function Nature Rev /Drug Discovery 2002, 1, 153- 161.

110. Holmes E, Tsang TM, Huang JJ, Leweke FM et al Metabolic Profiling of CSF: Evidence That Early Intervention May Impact on Disease Progression and Outcome in Schizophrenia PLoS Medicine 2006, 3, 8, 1420−1427.

111. Han X, Gross RW. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev. 2005; 24(3):367−412.

112. Serhan CN, Hong S, Lu Y. Lipid mediator informatics-lipidomics: novel pathways in mapping resolution. AAPS J. 2006; 8(2):E284−297.

113. Watson AD. Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006; 47(10):2101−2111.

114. Adibhatla RM, Hatcher JF, Dempsey RJ. Lipids and lipidomics in brain injury and diseases. AAPS J. 2006; 8(2):E314−321.

115. Collins CD, Purohit S, Podolsky RH, Zhao HS, Schatz D, Eckenrode SE, Yang P, Hopkins D, Muir A, Hoffman M, McIndoe RA, Rewers M, She JX. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol. 2006; 45(5):258−267.